Clinical Trial Update: CD30 CAR for CD30+ NSGCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CD30-targeted CAR-T cell therapy for CD30-positive nonseminomatous germ cell tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Germ Cell Tumor
• Nonseminomatous Germ Cell Tumor

Drugs mentioned

• CD30 CAR T-cell therapy

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Germ Cell Tumor, Nonseminomatous Germ Cell Tumor | Phase 2 | Status: COMPLETED